The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move that strengthens AbbVie's position in the global oncology market, the company has received European Commission marketing authorization for TEPKINLY as a combination therapy for patients with relapsed or refractory follicular lymphoma. The approval is based on Phase 3 trial results showing significant improvement in progression-free survival and high complete response rates compared to standard treatments. This authorization makes TEPKINLY the first bispecific-based chemotherapy-free option available for this specific condition in Europe.
This approval places AbbVie in direct competition with industry peers like Roche, which has had its drug Lunsumio approved in the EU for the same indication since 2022. Per market data, major pharmaceutical firms are vying for share in the follicular lymphoma treatment market, which is projected to grow at a CAGR of 7% through 2030 (according to Grand View Research). The oncology segment remains a critical growth driver for AbbVie as it seeks to offset revenue declines from Humira due to biosimilar competition.
Shares of ABBV stood at $261.07 (at close July 2, 2026), trading near the day's high of $261.64. Investors are now watching the speed of the drug's rollout across European markets and its subsequent impact on next quarter's earnings. While the upcoming economic calendar shows no direct healthcare catalysts, technical support for the stock remains at $250.51, representing the daily low from the July 2, 2026 session.